Abstract 1503TiP
Background
Cemiplimab is an anti–programmed cell death-1 (PD-1) antibody approved as first-line monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-ligand 1 (PD-L1) tumour cell expression. A high unmet medical need remains for patients with no or limited response to anti–PD-1/PD-L1 therapy. As prognosis is poor for these patients, there is growing interest in combining anti–PD-1 compounds with therapeutic cancer vaccines. BNT116 is an investigational mRNA-based therapeutic cancer vaccine consisting of a fixed set of 6 liposomally formulated RNAs, each encoding a different tumour-associated antigen frequently expressed in NSCLC.
Trial design
This is a randomised, multicentre, open-label phase 2 study of cemiplimab plus BNT116 versus cemiplimab alone in treatment-naive patients with stage IIIB, IIIC, or IV squamous or non-squamous NSCLC, who are ineligible for surgical resection or definitive chemoradiation. Patients must have PD-L1 expression on ≥50% of tumour cells (determined by analysis of resected tumour samples) and no actionable EGFR, ALK, or ROS1 aberrations. Patients in arm A will receive cemiplimab beginning Cycle 1 Day 1 (C1D1). Patients in arm B will receive cemiplimab beginning C1D1 and BNT116. The primary endpoint is objective response rate per blinded independent review committee of cemiplimab plus BNT116 versus cemiplimab alone. Secondary endpoints will assess other antitumour activities of cemiplimab plus BNT116 versus cemiplimab alone, as measured by objective response rate per investigator assessment, duration of response, progression-free survival, and overall survival, as well as safety and tolerability. Enrollment of up to 100 patients is planned. Enrolment is ongoing.
Clinical trial identification
NCT05557591.
Editorial acknowledgement
Medical writing support was provided by Talya Underwood of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc., and BioNTech SE.
Disclosure
M.M. Awad: Financial Interests, Personal, Advisory Role: Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Nektar, Maverick, Blueprint Medicines, Syndax, AbbVie, Gritstone, ArcherDX, Mirati, NextCure, EMD Serono; Financial Interests, Personal, Research Funding: Bristol Myers Squibb, Lilly, Genentech, AstraZeneca. Y. Hao, S. Li, M. Kaul, F. Seebach, P. Goncalves, P. Rietschel: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. P. Brück: Financial Interests, Personal, Full or part-time Employment: BioNTech SE; Financial Interests, Personal, Stocks/Shares: BioNTech SE.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21